Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Ketamin mod metamfetaminbrugsforstyrrelse (KMD)

26. oktober 2026 opdateret af: Madhukar H. Trivedi, MD, University of Texas Southwestern Medical Center

NIDA CTN-0132 Randomiseret, dobbeltblindet, aktivt placebokontrolleret forsøg med ketamin for metamfetaminbrugsforstyrrelser (KMD)

This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD.

The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Effective management for methamphetamine use disorder (MUD) remains elusive, despite widespread misuse of this stimulant. Psychological interventions have demonstrated modest benefits, and relapse rates are high. There are currently no Food and Drug Administration (FDA)-approved pharmacotherapies for MUD. This study explores the efficacy, safety, and feasibility for intravenous (IV) ketamine as a treatment for MUD and will help to determine the effect size for a larger, multi-site trial of intravenous (IV) ketamine in MUD.

Participants will receive either IV ketamine (0.50mg/kg) or IV midazolam (0.02mg/kg) over 45 minutes per infusion for a total of eight (8) infusions over six (6) weeks. Medical management sessions with a study clinician will be provided to all participants once weekly (from Weeks 1 through 6).

The use of IV ketamine in this trial is consistent in dose (0.5 mg/kg) and duration of infusion (45-minute-long) to other studies of ketamine for psychiatric disorders (such as major depressive disorder and post-traumatic stress disorder, both of which are often comorbid in individuals with MUD) and substance use disorder. However, IV ketamine has not been directly evaluated as mono-pharmacotherapy in those with MUD yet.

Additionally, participants will be asked to participate in cognitive behavioral therapy (CBT) sessions once weekly (from Weeks 1 through 12) on a non-infusion day.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

120

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • San Leandro, California, Forenede Stater, 94578
        • Alameda Health System
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87106
        • Interdisciplinary Substance Use and Brain Injury Facility
    • New York
      • New York, New York, Forenede Stater, 10029
        • Addiction Institute of Mount Sinai
    • South Carolina
      • Greenville, South Carolina, Forenede Stater, 29617
        • Prisma Health
    • Texas
      • Dallas, Texas, Forenede Stater, 75247
        • UT Southwestern Medical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion criteria

Study participants must:

  1. Be 18 to 65 years old
  2. Be able to sufficiently understand, speak, and read English
  3. Be interested in reducing or stopping methamphetamine use
  4. Meet criteria for methamphetamine use disorder
  5. Use acceptable methods of contraception during participation in the study

Exclusion criteria

Study participants must not:

  1. Have been in a research study of pharmacological or behavioral treatment for addiction within 6 months prior to written informed consent
  2. Be currently in jail, prison, or inpatient overnight facility as required by court of law
  3. Have upcoming surgery planned or scheduled
  4. Be currently pregnant, breastfeeding, or planning on conception, if biologically female

Additional inclusion and exclusion criteria will be assessed by the study investigators at the screening visit.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Ketamine

Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV ketamine will be administered 8 times over 6 weeks.

Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.

Andre navne:
  • Ketelar
Aktiv komparator: Midazolam

Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV midazolam will be administered 8 times over 6 weeks.

Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.

Andre navne:
  • Bevandret

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Treatment Response
Tidsramme: 2 weeks

Defined as having at least three methamphetamine-negative urine samples out of four samples obtained during Weeks 3 and 4.

2 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Non-serious adverse outcomes associated with IV ketamine treatment for methamphetamine use
Tidsramme: 6 weeks

Defined by non-serious adverse events (associated with the IV ketamine treatment) reported during the study intervention phase (weeks 1 to 6). Participants will be assessed for adverse events at each study visit.

6 weeks
Adherence to treatment
Tidsramme: 6 weeks

Defined by completion of at least five out of eight IV ketamine or IV midazolam infusions.

6 weeks
Total abstinence
Tidsramme: 2 weeks

Defined as four out of four methamphetamine-negative urine samples obtained during Weeks 3 and 4 (since missing urine drug screens will be counted as positive).

2 weeks
Abstinence from methamphetamine use
Tidsramme: 12 weeks

Defined by the self-reported days of methamphetamine use as reported on the Timeline Followback (TLFB) from Week 1 to Week 4, Week 5 to Week 6, and Week 7 to Week 12.

12 weeks
Differences in methamphetamine-negative urine samples from Weeks 1 to 6 and between ketamine and midazolam arms.
Tidsramme: 6 weeks

Urine samples will be collected twice a week at in-person visits.

6 weeks
Differences in methamphetamine-negative urine samples from Weeks 1 and 2 versus Weeks 3 and 4.
Tidsramme: 4 weeks

Urine samples will be collected twice a week at in-person visits.

4 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Madhukar Trivedi, MD, Professor (Tenured)

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

11. september 2024

Primær færdiggørelse (Faktiske)

6. september 2026

Studieafslutning (Faktiske)

15. oktober 2026

Datoer for studieregistrering

Først indsendt

3. juli 2024

Først indsendt, der opfyldte QC-kriterier

3. juli 2024

Først opslået (Faktiske)

11. juli 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

27. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

26. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • STU-2023-1086

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .